Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva

Pranay R. Randad, Nora Pisanic, Kate Kruczynski, Yukari C. Manabe, David Thomas, Andrew Pekosz, Sabra L. Klein, Michael J. Betenbaugh, William A. Clarke, Oliver Laeyendecker, Patrizio P. Caturegli, H. Benjamin Larman, Barbara Detrick, Jessica K. Fairley, Amy C. Sherman, Nadine Rouphael, Srilatha Edupuganti, Douglas A. Granger, Steve W. Granger, Matthew Collins, View ORCID ProfileChristopher D. Heaney
doi: https://doi.org/10.1101/2020.05.24.20112300
Pranay R. Randad
1Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nora Pisanic
1Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate Kruczynski
1Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukari C. Manabe
2Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
3Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Thomas
2Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Pekosz
1Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
4Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabra L. Klein
4Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
5Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Betenbaugh
6Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William A. Clarke
3Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Laeyendecker
2Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
7Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
8Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrizio P. Caturegli
3Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
9Division of Immunology, Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Benjamin Larman
3Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
9Division of Immunology, Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Detrick
3Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
9Division of Immunology, Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica K. Fairley
10Hubert Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy C. Sherman
11The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Decatur, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadine Rouphael
11The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Decatur, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srilatha Edupuganti
11The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Decatur, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas A. Granger
12Institute for Interdisciplinary Salivary Bioscience Research, University of California Irvine, Irvine, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve W. Granger
13Salimetrics, LLC, Carlsbad, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Collins
11The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Decatur, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher D. Heaney
1Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
6Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA
14Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher D. Heaney
  • For correspondence: cheaney1@jhu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Non-invasive SARS-CoV-2 antibody testing is urgently needed to estimate the incidence and prevalence of SARS-CoV-2 infection at the general population level. Precise knowledge of population immunity could allow government bodies to make informed decisions about how and when to relax stay-at-home directives and to reopen the economy. We hypothesized that salivary antibodies to SARS-CoV-2 could serve as a non-invasive alternative to serological testing for widespread monitoring of SARS-CoV-2 infection throughout the population. We developed a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology and tested 167 saliva and 324 serum samples, including 134 and 118 negative saliva and serum samples, respectively, collected before the COVID-19 pandemic, and 33 saliva and 206 serum samples from participants with RT-PCR-confirmed SARS-CoV-2 infection. We evaluated the correlation of results obtained in saliva vs. serum and determined the sensitivity and specificity for each diagnostic media, stratified by antibody isotype, for detection of SARS-CoV-2 infection based on COVID-19 case designation for all specimens. Matched serum and saliva SARS-CoV-2 antigen-specific IgG responses were significantly correlated. Within the 10-plex SARS-CoV-2 panel, the salivary anti-nucleocapsid (N) protein IgG response resulted in the highest sensitivity for detecting prior SARS-CoV-2 infection (100% sensitivity at ≥10 days post-SARS-CoV-2 symptom onset). The salivary anti-receptor binding domain (RBD) IgG response resulted in 100% specificity. Among individuals with SARS-CoV-2 infection confirmed with RT-PCR, the temporal kinetics of IgG, IgA, and IgM in saliva were consistent with those observed in serum. SARS-CoV-2 appears to trigger a humoral immune response resulting in the almost simultaneous rise of IgG, IgM and IgA levels both in serum and in saliva, mirroring responses consistent with the stimulation of existing, cross-reactive B cells. SARS-CoV-2 antibody testing in saliva can play a critically important role in large-scale “sero”-surveillance to address key public health priorities and guide policy and decision-making for COVID-19.

40-word summary A multiplex immunoassay to detect SARS-CoV-2-specific antibodies in saliva performs with high diagnostic accuracy as early as ten days post-COVID-19 symptom onset. Highly sensitive and specific salivary COVID-19 antibody assays could advance broad immuno-surveillance goals in the USA and globally.

Competing Interest Statement

In the interest of full disclosure, D.A.G. is founder and Chief Scientific and Strategy Advisor at Salimetrics, LLC and Salivabio, LLC and these relationships are managed by the policies of the committees on conflict of interest at Johns Hopkins School of Medicine and the University of California at Irvine. N.R. received funds from Sanofi Pasteur, Quidel, Merck and Pfizer.

Funding Statement

Funding for this study was provided by the Johns Hopkins University Provosts Office and the FIA Foundation. P.R.R., N.P., K.K., and C.D.H. were supported by a gift from the GRACE Communications Foundation. C.D.H., N.P., and B.D. were additionally supported by National Institute of Allergy and Infectious Diseases (NIAID) grants R21AI139784 and R43AI141265, and National Institute of Environmental Health Sciences (NIEHS) grant R01ES026973. C.D.H. was also supported by NIAID grant R01AI130066 and NIH grant U24OD023382. A.P. and S.L.K. were supported by NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N2772201400007C. O.L. was supported by the Division of Intramural Research, NIAID. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study has been approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) (IRB No. IRB00012253) Johns Hopkins Medicine IRB (IRB No. IRB00247886) and by the Emory University Institutional Review Board (IRB No. 00110683).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interest: In the interest of full disclosure, D.A.G. is founder and Chief Scientific and Strategy Advisor at Salimetrics, LLC and Salivabio, LLC and these relationships are managed by the policies of the committees on conflict of interest at Johns Hopkins School of Medicine and the University of California at Irvine. N.R. received funds from Sanofi Pasteur, Quidel, Merck and Pfizer.

  • Sources of funding: Funding for this study was provided by the Johns Hopkins University Provost’s Office and the FIA Foundation. P.R.R., N.P., K.K., and C.D.H. were supported by a gift from the GRACE Communications Foundation. C.D.H., N.P., and B.D. were additionally supported by National Institute of Allergy and Infectious Diseases (NIAID) grants R21AI139784 and R43AI141265, and National Institute of Environmental Health Sciences (NIEHS) grant R01ES026973. C.D.H. was also supported by NIAID grant R01AI130066 and NIH grant U24OD023382. A.P. and S.L.K. were supported by NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N2772201400007C. O.L. was supported by the Division of Intramural Research, NIAID. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.

  • Ethical Statement: This study has been approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) (IRB No. IRB00012253) Johns Hopkins Medicine IRB (IRB No. IRB00247886) and by the Emory University Institutional Review Board (IRB No. 00110683).

Data Availability

Requests for de-identified data should be submitted to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 26, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva
Pranay R. Randad, Nora Pisanic, Kate Kruczynski, Yukari C. Manabe, David Thomas, Andrew Pekosz, Sabra L. Klein, Michael J. Betenbaugh, William A. Clarke, Oliver Laeyendecker, Patrizio P. Caturegli, H. Benjamin Larman, Barbara Detrick, Jessica K. Fairley, Amy C. Sherman, Nadine Rouphael, Srilatha Edupuganti, Douglas A. Granger, Steve W. Granger, Matthew Collins, Christopher D. Heaney
medRxiv 2020.05.24.20112300; doi: https://doi.org/10.1101/2020.05.24.20112300
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva
Pranay R. Randad, Nora Pisanic, Kate Kruczynski, Yukari C. Manabe, David Thomas, Andrew Pekosz, Sabra L. Klein, Michael J. Betenbaugh, William A. Clarke, Oliver Laeyendecker, Patrizio P. Caturegli, H. Benjamin Larman, Barbara Detrick, Jessica K. Fairley, Amy C. Sherman, Nadine Rouphael, Srilatha Edupuganti, Douglas A. Granger, Steve W. Granger, Matthew Collins, Christopher D. Heaney
medRxiv 2020.05.24.20112300; doi: https://doi.org/10.1101/2020.05.24.20112300

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (144)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (72)
  • Dermatology (49)
  • Emergency Medicine (147)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (174)
  • Epidemiology (4906)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (689)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (322)
  • Health Systems and Quality Improvement (209)
  • Hematology (86)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5408)
  • Intensive Care and Critical Care Medicine (333)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (128)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (201)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (787)
  • Public and Global Health (1832)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (257)
  • Rheumatology (87)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (38)